Treatment of True Precocious Puberty with a Potent Luteinizing Hormone-Releasing Factor Agonist: Effect on Growth, Sexual Maturation, Pelvic Sonography, and the Hypothalamic-Pituitary-Gonadal Axis

摘要: We used the LHRH agonist D-Trp6-Pro6-N-ethylamide (LHRH-A) to treat 19 children (12 girls and 7 boys) with true precocious puberty. Fourteen patients had idiopathic puberty, 4 a hamartoma of tuber cinereum, 1 hypothalamic astrocytoma. Basal gonadotropin secretion responses native decreased within week initiation LHRH-A therapy, sex steroid 2 weeks or prepubertal range. Ultrasonographic evaluation uterus indicated postmenarchal size shape in all 11 studied before treatment, which reverted configuration 5 during therapy. The enlarged ovaries multiple ovarian follicular cysts regressed. Sexual characteristics ceased advancing toward state receiving therapy for 6-36 months. All menarche no further menses. Three hot flashes after LHRH-A-induced reduction plasma estradiol concentration. Height velocity, SDs above mean height velocity age, age therapy; skeletal maturation 12 months was sustained continued over 18-36 In patients, subnormal growth rate (less than 4.5 cm/yr) occurred Six cutaneous reactions LHRH-A, but demonstrable circulating antibodies LHRH-A. whom discontinued because skin reactions, sexual resumed at previous ensuing 6-12 months; subsequently, they were desensitized second course their secondary development levels again quickly decreased. proved an effective safe treatment puberty boys as well central whether type cinereum neoplasm.